Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627231 | 0.89 | P2RX1 (0.53) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19612094 | 0.87 | TMPRSS4 (0.52) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19612110 | 0.87 | TMPRSS4 (0.57) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL17770407 | 0.86 | CASP3 (0.57) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL17770431 | 0.83 | LRRK2 (0.71) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19612140 | 0.82 | RAB9A (0.55) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19630790 | 0.80 | RAB9A (0.51) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19627233 | 0.80 | MAPT (0.58) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19612095 | 0.78 | TMPRSS4 (0.57) | MEN1KMT2AP2RX1P2RX4P2RX7 | |
| SCHEMBL19631082 | 0.78 | TMPRSS4 (0.55) | MAPTMEN1KMT2AALDH1A1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-109415363-B | Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer | 罗格斯，新泽西州立大学 | 2021-07-20 | — | — | CN | disclosed |
| EP-3458454-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, The State University of New Jersey (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | RAB9A 4289/4885NPC1 719/4885MAPT 2009/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | RAB9A 4019/4885NPC1 684/4885MAPT 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.